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Abstract Bone metastases are common in many advanced
solid tumours, being breast, prostate, thyroid, lung, and
renal cancer the most prevalent. Bone metastases can
produce skeletal-related events (SREs), defined as patho-
logical fracture, spinal cord compression, need of bone
irradiation or need of bone surgery, and hypercalcaemia.
Patients with bone metastases experience pain, functional
impairment and have a negative impact on their quality of
life. Several imaging techniques are available for diagnosis
of this disease. Bone-targeted therapies include zoledronic
acid, a potent biphosfonate, and denosumab, an anti-
RANKL monoclonal antibody. Both reduce the risk and/or
delay the development of SREs in several types of tumours.
Radium 233, an alpha-particle emitter, increases overall
survival in patients with bone metastases from resistant
castration prostate cancer. Multidisciplinary approach is
essential and bone surgery and radiotherapy should be
integrated in the treatment of bone metastases when nec-
essary. This SEOM Guideline reviews bone metastases
pathogenesis, clinical presentations, lab tests, imaging
techniques for diagnosis and response assessment, bone-
targeted agents, and local therapies, as radiation and sur-
gery, and establishes recommendations for the manage-
ment of patients with metastases to bone.
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Introduction
Patients with solid tumours are highly susceptible to
develop bone metastases. While any malignancy may
metastasize to bone, it is most prevalent in advanced breast
(70–80%), prostate (70–80%), thyroid (60%), lung
(10–50%), and renal cancers (30%) [1–3]. Incidence of
bone metastases is also increasing in other cancers, prob-
ably owing to improved tumour control at other disease
sites. Proximal femur, pelvis, vertebrae, and skull are fre-
quent locations, being metastases in distal bones rare [4].
Bone metastasis is a devastating condition that can have
a negative impact on the lives of patients with advanced
cancer in many ways. They are also associated with sig-
nificant consumption of healthcare resources that generate
a substantial economic burden for the Healthcare System
[5].
Normal bone formation is a coordinated dynamic pro-
cess of active bone production by osteoblasts and bone
remodeling and resorption by osteoclasts. This fine balance
is mediated by a variety of local and systemic factors, such
as transforming growth factor-beta (TGF-b), insulin growth
factor (IGF), bone morphogenic protein, platelet-derived
growth factor (PDGF), prostaglandins, and parathyroid
hormone, as well as receptor activator of nuclear factor
kappa-B ligand (RANK-L), a member of tumour necrosis
factor (TNF) family, that is a key factor for osteoclast
production.
When cancer metastasizes to bone, deregulated bone
remodeling occurs. Metastasizing tumour cells mobilize and
sculpt the bonemicroenvironment to enhance tumour growth
and to promote bone invasion. Bone metastases disrupt this
complex interplay through an organized and multistep pro-
cess involving tumour intravasation, cell survival in the
circulatory system, extravasation into surrounding tissue,
initiation and maintenance of growth, vascularization, and
angiogenesis. Tumour invasion into bone is associated with
osteoclast and osteoblast recruitment, resulting in the liber-
ation of growth factors from the bone matrix, which can feed
back to enhance tumour growth resulting in the ‘vicious
cycle’ of bone metastasis [6].
Clinical and laboratory manifestations of bone
metastases
Pain is the most common symptom of bone metastases. It is
usually focal, well located, and associated with functional
impairment, and may appear before imaging evidence of
the disease.
Pathological fracture, spinal cord compression, need of
bone irradiation, and need of bone surgery, usually to
correct fractures or spinal deformities, are bone compli-
cations gathered in the category of skeletal-related events
(SREs). Hypercalcaemia is not considered as a SRE in
clinical trials, because it is easily reversible and can be a
paraneoplasic syndrome in the absence of bone metastases.
The development of an SRE determines poor prognosis
(impact in quantity of life) [7] and a higher probability of a
new bone event [impact in quality of life (QOL)].
Laboratory tests
Elevated levels of bone turnover markers are proportional
to the extent of skeletal involvement in patients with bone
metastases [8]. Bone alkaline phosphatase, an isoform of
alkaline phosphatase, is a relatively specific indicator of
osteogenesis and shows a good correlation with the pres-
ence and spread of bone metastases, mainly in breast and
prostate cancer, although its clinical application is limited
by its relatively low specificity [9]. Urinary markers
telopeptides, N-terminal (NTx) and C-terminal (CTx), are
bone breakdown products of type I collagen released dur-
ing the bone resorption. Risk of skeletal complications and
disease progression is duplicated when NTx levels are
moderate/high [10] and normalization of NTx and CTx
excretion rates is associated with relief of symptoms and
reduced incidence of SREs [11]. Bone turnover markers
may be helpful in monitoring the efficacy of bisphospho-
nates (BPs). However, changes in urinary levels of NTx
and CTx require long periods of time [12] and their use in
the routine care is still controversial.
MiRNA, small non-coding RNA molecules, regulate
gene expression and can be detected in early stages of bone
invasion [13]. Several miRNAs (miR-10b, miR-16, and
miR-378) have been proposed for the diagnosis of bone
metastases in patients with breast cancer with accept-
able sensitivity (64%) and specificity (69%), and miR-326
has been proposed as a biomarker for monitoring meta-
static progression in bones [14].
Bone metastasis imaging
Bone metastases imaging is essential for tumour staging and
formonitoring the therapeutic response. Bonemetastases are
typically classified as lytic, sclerotic, or mixed. Lytic
metastases prevail in the absence of bone production, being
typical of myeloma, kidney cancer, and melanoma. On the
contrary, metastases acquire sclerotic patterns wherever the
osteoblastic activity dominates, as in prostate cancer. Often,
lesions show a mixed appearance, as it can happen in breast
or lung cancer. The differential diagnosis with benign pro-
cesses can be complex, especially in the elderly.
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Diagnosis
Plain X-rays are frequently used, but their sensitivity is
low.
Concerning nuclear medicine, two imaging methods
applying different physical principles and reconstruction
procedures are available: scintigraphy/single photon emis-
sion computed tomography (SPECT) and positron emission
tomography (PET). Both allow hybrid image systems by
combining them with computed tomography (CT) or
magnetic resonance imaging (MRI): SPECT/CT, PET/CT,
and PET/MRI. Tracers used within these techniques can be
distinguished according to their functional mechanism, by
exploiting different pathophysiological principles.
Radionuclide bone scans (bone scintigraphy and SPECT)
make use of 99mTechnetium (99mTc) diphosphonate as a
tracer, which is bone matrix-specific, being the deposit
proportional to blood flow and the osteoblastic activity
[15]. This tracer identifies the bone reaction to the tumour,
but is unable to detect the bone-marrow involvement [16].
As a result, 99mTc-based imaging does not reliably distin-
guish between reparative osteoblastic activities (flare)
versus (vs) true disease progression. Other techniques are
generally required for solitary lesions or equivocal
scintigraphy findings. Fused SPECT-CT may yield lower
false-positive rates, since it allows morphological correla-
tions [17, 18].
Other techniques, such as 18-fluoro-2-deoxy-D-glucose
([18] F-FDG) PET or MRI, can detect metastases prior to
the onset of the osteoblastic activity. Compared to SPECT
[18], F-FDG PET has a greater spatial resolution and
allows the quantification of maximum standard uptake
values (mSUV), which discriminates between malignant
and benign lesions. Unlike bone scintigraphy, it is assumed
that [18] F-FDG uptake is a specific marker for tumour
glycolysis, but does not assess the microenvironment sta-
tus. In this context, [18] FDG-PET has shown higher sen-
sitivity than bone scintigraphy (93 vs 81%) [19]. The
reduction in false-positive rates may be due to both
intrinsic tracers’ mechanisms and the fusion with CT
imaging. On the other hand, the sensitivity of PET/CT is
higher for lytic tumours in comparison with blastic lesions;
several factors may be involved, being one of them the
greater biological aggressiveness of the former [20].
Accuracy values will also depend on the tumour and his-
tological subtypes. For example, sensitivity is also lower in
certain tumours, such as prostate cancer, in which [11]
C-choline PET may yield better results.
MRI is the technique of choice whenever a precise
anatomical delineation is necessary. Morphologic MRI is
superior to radiographs or scintigraphy in the assessment
of focal lesions, since it allows the detection of bone-
marrow replacement by tumour cells before the onset of
trabecular changes. Since specificity can be lower to [18]
F-FDG PET/CT, MRI studies should not be read iso-
lated, but integrated with other imaging modalities [16].
New functional techniques, such as whole-body diffu-
sion-weighted (DW) or dynamic contrast-enhanced
(DCE) MRIs, are beginning to be explored with exciting
possibilities [21].
It is important to prove the diagnosis of metastases by
biopsy in impending or complete pathologic fracture in a
patient with solitary lesion, because infections and primary
sarcomas can have a similar appearance. If a patient has a
history of cancer without prior documentation of bone
metastases, TC-guided fine needle aspiration and core
biopsy are excellent method to document the presence of
metastatic disease.
Response assessment
Bone involvement is the only one that contemplates
specific measurability criteria with regard to tumour
response assessment [22]. Conventional radiographies are
insensitive and do not allow early evaluations [23]. One of
the issues is that tumour-induced osteoblastic activity is
indistinguishable from reparative osteoblastic changes. As
a result, bone scintigraphy assessing the number and
intensity of hotspots has shown low performance in this
situation. Ongoing sclerosis may constitute a sign of
response. However, in approximately 50% of responders,
no changes in bone scans could be observed, while in
around 40% of non-responders, progression was not
apparent for 6–8 months, in an early study [24]. A transient
morphologic worsening by inflammatory and reparative
phenomena of lesions that are actually responding is
sometimes referred to as ‘‘flare’’. This is a limitation for the
use of bone scintigraphy in clinical practice or as endpoint
in clinical trials, especially when the lytic component
dominates.
PET/CT can predict responses earlier [25], but at pre-
sent, evidence is still lacking to recommend the routine use.
Metastases in progression generally become more avid to
[18] F-FDG. Likewise, an increase in sclerosis of the
lesions over time without mSUV increases is usually
associated with true responses, although it does not appear
that this is always the case [16]. The Positron Emission
Tomography Response Criteria in Solid Tumours (PER-
CIST) intend to homogenize the standards of evaluation by
this method [26]. Studies are ongoing to determine the
value of other promising techniques, such as [18] F-NaF
PET (NCT00882609).
On the other hand, morphologic MRI seems to be useful
to detect tumour progression but not so much to predict
early response [27]. DW-MRI changes or multiparametric
approaches may be helpful, but more data are warranted
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due to the great heterogeneity in metastatic patterns and
behaviors.
In summary, there are currently new techniques with
enhanced sensitivity and specificity for staging the skeleton
and evaluating the response, although more experience is
required before generalizing their use. For screening pur-
poses, 99mTC, SPECT/CT, or [18] F-FDG-PET/CT is
usually recommended, depending on the type of tumour,
histology, and clinical setting. MRI confirmation is sug-
gested for equivocal or solitary lesions. Whole-body MRI
with T1, T2, or DWI-weighted sequences has shown
promising results, but further evaluation is still recom-
mended. Hybrid imaging techniques (e.g., SPECT/CT or
PET/CT) may yield higher sensitivity and improved
specificity. Some data indicate that [18] F-FDG PET/CT
can be a good method for early response assessment. In the
future, new techniques of fusion, integrating new tracers,
surely will enable us to take another step forward.
Medical treatment options for bone metastases
Appropriate management of bone metastases is essential,
since about 40% of patients with bone metastases will
develop a bone event in the absence of preventive therapy
[28].
Biphosphonates
Biphosphonates structure is similar to endogen pyrophos-
phate. Therefore, they are able to bind to mineralized bone
matrix in areas of high bone turnover and potently inhibit
of osteoclast-mediated bone resorption.
Zoledronate or zoledronic acid (ZA), the most effective
third-generation bisphosphonate in preventing SRE, is
administered at a dose of 4 mg intravenous (iv) during
15 min every 3 (q3w) or 4 weeks (q4w), with supplemental
calcium and vitamin D. So far, the best dosing interval is
still to be determined [29]. Zoledronic acid has Europe and
United States regulatory approval for prevention of SREs.
It is recommended to start at the bone metastases diagnosis,
even the patient is asymptomatic, and should be continued
indefinitely during the disease [30].
The most relevant adverse event of zoledronate is
nephrotoxicity, a limitation for its use in cancer patients
receiving cisplatin therapy, and particularly for lung cancer
patients that are associated with comorbidities, older age,
and tobacco use. Its administration needs renal function
monitoring and dose adjustments. Acute-phase reactions
(chills, fever, bone pain, and fatigue), hypocalcaemia, and
osteonecrosis of jaw (ONJ) are other side effects. Risk of
ONJ increases if previous dental trauma, infection, or
surgery and with long-term administration of the drug.
Breast cancer
Two studies were conducted in patients with metastatic
breast cancer (MBC). The first study included also multiple
myeloma and was designed as a non-inferiority trial com-
paring zoledronic acid and pamidronate [31]. Although
there were no differences across the entire study population
in the proportion of patients with a SRE (43 vs 45%)—
primary endpoint—among patients who had breast carci-
noma with at least one osteolytic lesion, the proportion
with an SRE was lower with zoledronate compared with
pamidronate (48 vs 58%), but without statistical signifi-
cance (p = 0.058). The median time to first SRE was
significantly longer with ZA (310 vs 174 days, p = 0.013).
In the second study in 228 Japanese women with bone
metastases, zoledronic acid at doses of 4 mg iv q4w over a
year reduced the risk of SREs by 39% compared to placebo
(RR 0.61; p = 0.027) and the rate of patients experiencing
at least one SRE, compared to placebo (29.8 vs 49.6%,
p = 0.003), significantly delaying the onset of the first SRE
[32].
Recently, two randomized trials have evaluated the
administration of zoledronic every 12 weeks instead
4-week interval. In the OPTIMIZE 2 [33], female patients
with bone metastases from MBC who previously received
C9 doses of iv BPs (zoledronic or pamidronate) during the
first 10–15 months of therapy were randomized (1:1) to
receive zoledronate 4 mg iv q4w or q12w. The primary
endpoint was the proportion of women with C1 SRE on
study. The SRE rate was 22 and 23.2% in the zoledronic
q4w and q12w arms, respectively. In the second trial,
Himelstein et al. [34] compared during 24 months zole-
dronic q4w and q12w from the first dose of the drug. A
total of 1822 patients with MBC (n = 833), myeloma, and
other solid tumours were randomized. The proportion of
SRE was 29.5 vs 28.6% (p = 0.79) for monthly and every
3 months, respectively, showing that zoledronic adminis-
tered every 3 months is non-inferior to zoledronic admin-
istered monthly for 24 months.
In summary, zoledronic acid reduces SREs incidence in
MBC patients with lytic bone metastases. Recent results
support the dose of 4 mg every 12 weeks in patients who
have received at least 1 year of q3w zoledronic and also
this option could be considered in MBC from the beginning
of the treatment.
Prostate cancer
About 90% of castration-resistant prostate cancer (CRPC)
patients present imaging evidence of bone metastatic dis-
ease [35]. Zoledronic acid, denosumab, and radium-223 are
the approved bone-targeted agents for bone metastases
from this disease [36].
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In a randomized, double blind, placebo-controlled,
phase III trial, including 643 patients with bone metastases
from CRPC, 4 mg zoledronic acid decreased incidence of
SREs (33.2 vs 44.2%, p = 0.021) and increased the median
time to the first SRE (488 vs 321 days, p = 0.01) when
compared to placebo [37]. No differences in overall sur-
vival (OS), progression free survival (PFS) or QOL were
observed between the groups of treatment. With a
24-month follow-up, zoledronic acid reduced SRE risk in
36% (RR 0.64; p = 0.002) and bone pain.
In contrast, zoledronic acid has not demonstrated any
benefit in castration-sensitive prostate cancer. The phase III
CALGB 90202 trial (Zoledronate in Preventing Skeletal
[Bone]-Related Events in Men Who Are Receiving
Androgen Deprivation Therapy For Prostate Cancer and
Bone Metastases) [38] was early interrupted since no sta-
tistically significant differences between ZA and placebo
were observed in the time to first SRE, primary endpoint,
after 645 men recruited and 299 SREs observed
(31.9 months in ZA vs 29.8 months in placebo; HR 0.97).
Overall survival was similar (HR 0.88; 95% CI 0.70–1.12).
Therefore, zoledronic acid is not approved for patients with
bone metastases from castration-sensitive prostate cancer.
In summary, zoledronic acid is the only iv biphospho-
nate approved for SREs prevention for CRPC. However, it
is not approved for patients with bone metastases from
castration-sensitive prostate cancer.
Other solid tumours
Long-term efficacy results of a placebo-controlled phase III
trial, including 773 cancer patients other than breast and
prostate with skeletal metastases, showed that 4 mg zole-
dronic acid can significantly reduce the proportion of
patients who experience at least one SRE (39% in zole-
dronic arm vs 48% with placebo, p = 0.039). Moreover,
4 mg zoledronic acid significantly delayed the median time
to first SRE compared with placebo (236 vs 155 days,
respectively, p = 0.009) and reduced the risk of SREs by
31% versus placebo in the overall trial population [39].
Denosumab
Denosumab is a fully human, monoclonal, synthetic, IgG2
antibody that binds to RANKL, with high affinity and
specificity, and inhibits formation, function, and survival of
activated osteoclasts, bone destruction, and tumour growth.
Denosumab is recommended to be administered at a
dose of 120 mg as a single subcutaneous (sc) injection
once every 4 weeks taking supplemental calcium and
vitamin D. It was approved by European Medicines
Agency and Food and Drug Administration (FDA) for
prevention of SREs in patients with solid tumours [40, 41].
It is recommended to start its use at the bone metastases
diagnosis and should be continued indefinitely during the
disease.
Denosumab toxicity profile consists mainly of
hypocalcaemia and side effect, such as ONJ, occurs at
similar low rates of zoledronic acid. However, acute-phase
reactions and renal impaired are less frequent without the
need for dose adjustment for renal disfunction or renal
monitoring.
Breast cancer
A phase III study compared denosumab to zoledronic acid
in patients with bone metastases from MBC [42]. A total of
2046 patients were randomized to receive, q4w, deno-
sumab 120 mg sc plus placebo iv over 15 min (n = 1026)
or placebo sc plus zoledronic acid 4 mg iv over 15 min
(n = 1020). The primary objective was the time to first
SRE with a statistical consideration of non-inferiority.
Denosumab significantly delayed the time to first SRE
compared with zoledronic by 18% (p = 0.01). Risk
reduction in first and subsequent SREs consistently
favoured denosumab also. Overall incidence of adverse
events was similar between the two groups, including ONJ
(p = 0.13). There were an increased incidence of acute-
phase reactions in the zoledronic acid group and higher
incidence of hypocalcaemia in the denosumab group.
In summary, denosumab is considered superior to
zoledronic acid in delaying or preventing SREs in patients
with breast cancer metastatic to bone with the convenience
of a subcutaneous injection and no requirement for renal
monitoring, and without differences in ONJ rates.
Prostate cancer
Denosumab (120 mg sc) was compared 1:1 to 4 mg iv
zoledronic acid in a pivotal, double blind, placebo-con-
trolled, phase III study in 1901 patients with bonemetastases
fromRCPC, naı¨ve to biphosphonates [43]. Time to first SRE,
primary endpoint, was 20.7 months in denosumab group vs
17.1 months in ZA group (RR 0.82; CI 95% 0.71–0.95;
p = 0.008). No differences in OS or time to progression
were observed. ONJ was 2% in denosumab group and 1% in
zoledronic group (p = 0.09). Adverse events related with
acute-phase reactions were less common with denosumab (8
vs 18%; p\ 0.0001) and doses changes were no required in
denosumab patients if renal impairment.
In summary, and in agreement with recent guidelines for
the treatment of bone metastases [44], it is recommended
the administration of zoledronic acid or denosumab to
prevent or delay SREs in patients with bone metastases
from RCPC. Denosumab has superior clinical benefits and
better tolerance.
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Lung cancer
Denosumab has been studied in 1776 patients with skeletal
metastases from a solid tumours andmultiplemyeloma other
than breast and prostate cancer in a phase III trial comparing
denosumab vs zoledronic acid. Denosumab improved the
time to first SRE from 16.3 to 20.6 months (HR 0.84;
p = 0.0007) achieving the primary endpoint of non-inferi-
ority. Considering the effect of denosumab relative to zole-
dronic acid by tumour stratification factors for other solid
tumours, and taking into account only non-small cell lung
cancer (NSCLC) patients (n = 702), resulted in an HR of
0.84, p = 0.20 [41]. In an exploratory analysis performed for
OS, denosumabwas associatedwith improvedmedian OS vs
zoledronic acid in 811 patients with any lung cancer (8.9 vs
7.7 months, p = 0.01), in 702 patients with NSCLC (9.5 vs
8.0 months, p = 0.01), and 8.6 vs 6.4 months (p = 0.035) in
patients with squamous cell carcinoma; however, without
statistically significant differences for adenocarcinoma
patients (HR 0.81; p = 0.36) and small cell lung cancer
patients (HR 0.80; p = 0.075) [45].
Preclinical data [46] and these hypothesis-generating
outcomes warrant further investigation: two prospective
studies in lung cancer are ongoing to elucidate the thera-
peutic potential of denosumab beyond SRE prevention.
Other solid tumours
In the phase III trial, comparing denosumab with zole-
dronic acid considering the effect by tumour stratification
factors for patients with bone metastases from only solid
tumours other than MBC and prostate cancer, excluding
NSCLC and multiple myeloma (a total of 904 patients)
resulted in an improvement of the time to first SRE (HR
0.79; p = 0.04) [41]. In an ad hoc analysis of this study
excluding only multiple myeloma (a total of 1597 patients),
superiority of denosumab was observed delaying time to
first on-study SREs (HR 0.81; p = 0.017), and time to first-
and-subsequent SREs (RR 0.85, 95% CI, 0.72–1.00) and
also prevented pain progression [47].
In summary, denosumab is more effective than zole-
dronic acid in delaying or preventing skeletal morbidity in
patients with bone metastases from other solid tumours.
Radiopharmaceuticals (including radium 223)
Radiopharmaceuticals are other class of bone-targeted
therapies. Due to its similarity with the calcium, these
agents are up-taken in sites with osteoblastic activity,
where they destroy surrounding tissues because of their
radioactive activity.
Radiopharmaceuticals are classified depending on the
particles they emit. Strontium 89 and Samarium 109 are b-
emitter particles with high tissue penetrance, leading risk
of haematological toxicity, mainly thrombocytopenia [48].
These two agents did not demonstrated improved OS in
phase III clinical trials, but FDA approved them, since a
palliative relief of pain was achieved [49, 50].
Radium dichloride 223 emits alpha particles, with high
energy but low penetration (\100 lm or a range of 2–10
cells of diameter), and acts in the microenvironment of
bone metastases [51]. The recommended dosing is 50 kBq/
kg (1.35 microcuries/kg) in 1-min bolus iv administration
every 4 weeks, 6 doses. Due to the potential haematolog-
ical toxicity of radium 233, adequate bone-marrow func-
tion parameters—haemoglobin C10 g/dL, absolute
neutrophil count C1.5 9 109/L, and platelets[100 9 109/
L—are required.
The randomized, double blind, ALSYMPCA [52] trial
included 921 patients with bone metastases from RCPC,
without visceral disease, after progression to docetaxel or
unfit for this agent. Patients were assigned 2:1 to radium-
223 plus best standard care (BSC) vs placebo ? BSC,
which included extern radiotherapy (RT), BPs, corticoids,
antiandrogens, estroogens, estramustine, or ketoconazol. In
a preplanned interim analysis, overall survival, primary
endpoint, was superior with radium-223 [14 vs
11.2 months, (HR 0.70; 95% CI 0.55–0.88; p = 0.002). In
a recent update, median OS was 14.9 and 11.3 months with
radium-223 and placebo, respectively [53]. Time to first
SRE was also longer with radium-223 vs placebo (median,
15.6 vs 9.8 months; HR 0.66; 95% CI 0.52–0,83;
p\ 0.001). Radium 223 decreased requirements of exter-
nal RT for bone pain (HR 0.67, 95% CI 0.53–0.85) and risk
of spinal cord compression (HR 0.52, 95% CI 0.53–0.85).
This benefit was independent of previous docetaxel or
concomitant bisphosphonates treatment. Hematologic tox-
icity in patients treated with chemotherapy after radium-
223 was not higher than in the placebo group. Other side
effects were similar in both groups. QOL tests (FACT-P)
showed a significant improvement in the radium-223 arm
versus placebo arm. There are ongoing clinical trials
combining radium 223 with docetaxel and with other active
compounds for RCPC.
In summary, radium-223 is the first therapy against the
bone microenvironment that increases overall survival in
RCPC patients. As a result, radium-223 was approved for
patients with CRPC with symptomatic metastases and
without visceral disease by FDA in May 2013.
Other treatment options for bone metastases
The proper management of bone metastases requires mul-
tidisciplinary approach by radiologists, radiation oncolo-
gists, medical oncologists, surgeons, pain medicine
1248 Clin Transl Oncol (2016) 18:1243–1253
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specialists, and palliative care professionals. The goals of
palliative treatment are pain relief, preservation of func-
tion, and maintenance of skeletal integrity. Early inter-
vention may be useful in maintaining QOL and minimizing
side effects of analgesic medication.
External beam radiotherapy
Radiation therapy is the treatment of choice for palliation
of localized bone pain. It is effective in a majority of
patients, although a transient worsening of pain may occur
in some cases (30–40%), typically in the first few days after
RT, but this flare generally lasts 1 or 2 days [54]. Dex-
amethasone may reduce the frequency of pain flare.
Multiple prospective randomized trials have shown pain
relief equivalency for dosing schema including 30 Gy in
ten fractions, 24 Gy in six fractions, 20 Gy in five frac-
tions, and a single 8 Gy fraction for patients with previ-
ously un-irradiated painful bone metastases [55].
Reirradiation may be necessary for patients if the initial
treatment fails or there is a subsequent relapse after an
initial response. There are limited data on the optimal
schedule and dose for reirradiation [56–58].
Stereotactic body radiation therapy
A newer technology to treat bone metastases is stereotactic
body radiotherapy (SBRT). In selected cases with small-
volume skeletal metastasis, limited metastatic tumour
burden, and good performance status, SBRT provides a
way to deliver a radical treatment. Current published
results suggest that a single-fraction stereotactic radio-
surgery at up to 20 Gy can be used for relief of acute bone
pain, even for radio-resistant tumour types, such as mela-
noma and renal cell carcinoma. The optimal dose schedule
for specific tumour types is not known [59].
Traditionally, RT to the vertebral body is limited by the
tolerance of the spinal cord and reirradiation of the same
vertebra is discouraged due to the potential for spinal cord
injury. However, two small series reported good results
with salvage SBRT for previously irradiated spinal
metastases [60, 61].
Orthopaedic surgery
A preoperative evaluation and systemic staging is manda-
tory. The aims are to delineate the osseous and soft tissue
extent of the lesion and its relationship to adjacent struc-
tures, determine the overall skeletal involvement by
tumour, detect any other metastases that may require
concomitant treatment, and asses the patient´s overall
prognosis. Pathological fractures are not an emergency,
and proper workup is needed before any intervention.
Operative intervention for metastatic disease is gener-
ally a palliative procedure. Complete and impending
pathologic fractures should be treated with durable fixation
or reconstruction depending on the patient’s expected
survival. Resections are done in selected cases, particularly
for solitary metastases.
Surgery for spinal metastases
Surgical treatment may be indicated for patients with spinal
metastases that are causing instability or spinal cord com-
pression. An unstable spine should be stabilized either by
surgery with fixation or by percutaneous vertebral repair.
Vertebroplasty and Kyphoplasty are reserved for patients
with symptomatic vertebral body fractures without epidural
disease or retropulsion of bone fragments into the spinal
cord. Although clinical experience is limited, ASTRO
guidelines recommend that radiotherapy be used in con-
junction with these procedures [62].
Spinal cord compression is a devastating complication.
Standard treatment consists of corticosteroids and RT, with
which only about 50% of patients are able to walk and few
non-ambulatory patients ever walk again. The amount of
surgery ranges from simple decompression to a bloc
resection and fixation. Patients with solitary metastasis
with favorable histology, such as MBC, are more often
selected for the bloc resections in view of longer life and,
therefore, need to maintain QOL.
Results with laminectomy plus radiation did not seem to
differ from results with RT alone. Surgical treatment was
largely abandoned when several retrospective studies and a
small randomized trial did not show any benefit for
laminectomy alone or in combination with RT. However,
these non-randomized studies were subject to patient selec-
tion bias, heterogeneous tumour types, unclear inclusion
criteria, and imprecise endpoints. To determine the value of
surgery, a randomized trial comparing the efficacy of direct
decompressive surgery plus postoperative RT vs RT alone
was taken. It demonstrated that for patients with good per-
formance status and a life expectancy of at least 3 months,
direct decompressive surgery followed by postoperative RT
is clearly superior to RT alone in terms of maintaining
deambulation and need for corticosteroids and opioid anal-
gesics was significantly reduced in the surgical group [63].
Long bones
The usual surgical options vary from internal fixation with
a nail or plate with or without cement and endoprosthetic
arthroplasty. The exact choice depends on the location,
amount of bone loss, and responsiveness of lesion to sys-
temic therapy. As a general rule, nails are preferred in the
lower limbs and plates in the upper limb. Wherever
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possible, the maximum length of the bone is stabilized to
minimize a future fracture at another location [64].
Pelvic and periacetabular defects
Surgery is rarely required for pathologic fractures of the pelvis,
except for those involving the acetabulum. Most pathologic
acetabular fractures are addressed with a complex acetabular pros-
thetic arthroplasty reconstruction that distributes the stresses away
from thediseasedboneand into the intact boneof the superior ilium
when intact. Increasingly, painful osteolytic defects around pelvis
and acetabulum have begun to be treated with percutaneous pro-
cedures, including cementoplasty, radiofrequency ablation,
cryoablation, and focused ultrasound.
In summary, for patients with a single or limited number of
areas of painful bone metastases, external RT is indicated.
Using a single fraction of 8 Gy to the involved area may
provide equal palliation with improved patient convenience
and cost effective comparedwith fractioned schedules. SBRT
may be particularly useful in selected cases with radio-resis-
tant tumours, spinal cord compression, where there is a sig-
nificant concern about normal tissue toxicity and for those
who need retreatment for previously spinal metastases.
Surgical decompression and stabilization plus postoper-
ative RT should be considered for selected patients with
single level spinal cord compression or spinal instability,
unless the patients have too short of an anticipated life
expectancy. Kyphoplasty and vertebroplasty may be useful
for the treatment of lytic osteoclastic spine metastases or in
cases of spinal instability, where surgery is not feasible or
indicated; they do not obviate the need for external beamRT.
Radiotherapy is indicated for most patients after fixation of a
complete or impending pathologic fracture of any bone.
Prevention of cancer treatment-induced bone loss
In the adjuvant setting, cancer treatment-induced bone loss is
a frequent cause of morbidity, and prevention and treatment
of this condition with BPs and denosumab are also well
established. Besides postmenopausal patients, several stud-
ies, including two large studies by the Austrian Breast and
Colorectal Cancer Study Group (ABCSG) and the Cancer
and Leukemia Group B (CALGB), have shown an increase
in bone mineral density in premenopausal women.
Adjuvant bone-targeted therapy in breast cancer
Clinical trials of BPs as adjuvant therapy for breast cancer
have had mixed results. Clodronate, an oral first-generation
bisphosphonate, showed a DFS benefit vs placebo in one
large randomized trial [65], but not in another [66]. An
early trial of zoledronic acid added to adjuvant aromatase
inhibitor therapy for postmenopausal women to prevent
bone loss, showed a non-significant improvement in DFS
[67], a secondary endpoint. Larger trials comparing zole-
dronic acid to no therapy in postmenopausal women [68],
or in premenopausal women made menopausal with
gonadotropin-releasing hormone agonists [69], showed
significant DFS benefits, but no benefit was seen in a large
randomized trial of both premenopausal and post-
menopausal women [70].
The Early Breast Cancer Trialists’ Collaborative Group
[71] presented a meta-analysis comprised of individual
patient data derived from randomized adjuvant bisphos-
phonate trials in breast cancer done over the past 20 years.
The analysis received data on 18 766 women (18 206 in
randomized trials of 2–5 years of adjuvant BPs vs control),
with a median follow-up of 5.6 years, 3453 first recur-
rences, and 2106 deaths. For all patients, there were bor-
derline significant reductions with the addition of
bisphosphonates at 10 years for distant recurrence (20.4 vs
21.8%, p = 0.03), bone recurrence (7.8 vs 9.0%,
p = 0.004), breast cancer mortality (16.6 vs 18.4%,
p = 0.04), and all-cause mortality (20.8 vs 22.3%,
2p = 0.06).
In postmenopausal women, there were highly significant
reductions with the addition of bisphosphonates at 10 years
for bone recurrence (6.6 vs 8.8%, p = 0.0002) and for
breast cancer mortality (14.7 vs 18.0%, p = 0.002). This
benefit was independent of the type and schedule of
administration of BP, the oestrogen receptor status of the
primary tumour, the presence of axillary lymph node
involvement, and the use of concomitant systemic
chemotherapy. There was no reduction in the incidence of
contralateral breast cancer or in the risk of metastasis to
non-osseous sites. In the 13,341 women with available
fracture data, BPs reduced the risk of fracture from 7.3 to
6.3% (p = 0.02).
The absolute reduction in the risk of breast cancer
death at 10 years with the use of bisphosphonates in
postmenopausal women (3.3%) is similar to the benefit
seen with anthracycline polychemotherapy vs non-an-
thracycline polychemotherapy [72]. The publication of
the latest Oxford overview of prospective trials is being
awaited; at the presentation of the results, a 34% relative
reduction of bone metastases and a 17% improvement in
OS were demonstrated in the subgroup of post-
menopausal patients.
These results on breast cancer treatment could lead to
widespread adoption of bisphosphonates as a standard of
care for the adjuvant therapy of early stage breast cancer in
postmenopausal women.
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Should all postmenopausal women with early stage
breast cancer receive adjuvant bisphosphonates?
Bisphosphonate action seems to be bone centric, and as a
result, BPs do not appear to prevent contralateral breast
cancer, locoregional disease, or metastases to non-osseous
sites. One study indicating that overexpression of lysyl
oxidase by primary breast cancers can lead to increased
bone turnover in the bone micro-environmental niche and
increased establishment of bone metastases is intriguing,
and suggests a potential biomarker for response [73].
Increased bone turnover after menopause might also
explain the preferential benefit of BPs in reducing bone
recurrence in postmenopausal women. It will be interesting
to determine if osteoprotogerin analogues, such as deno-
sumab, provide DFS benefits similar to BPs in ongoing
clinical trials, such as ABCSG-18 [74], in which deno-
sumab significantly reduced fracture rates in post-
menopausal women receiving aromatase inhibitors.
This apparent success in altering the natural history of
breast cancer by modifying the tumour microenvironment
lends great credence to investigational efforts in breast
cancer and other cancers attempting to understand and
modify tumour–host micro-environmental interactions.
Other adjuvant studies
The study D-CARE (ClinicalTrials.gov Identifier:
NCT01077154) is a prospective, randomized, ongoing
phase III trial comparing denosumab vs placebo (in addi-
tion to standard adjuvant therapy) in 4509 patients with
operable breast cancer. The primary end-point of the trial is
bone metastases-free survival.
Recommendations
Zoledronic acid is the most active biphosphonate to prevent
morbidity from bone metastases in patients with breast,
castration-resistant prostate, lung, and other solid cancers.
It is administered at a dose of 4 mg iv every 3 or 4 weeks
when bone metastases are detected, even the patient is
asymptomatic, and should be continued during the disease.
In metastatic breast cancer, a dosis of 4 mg every 12 weeks
may be considered.
Denosumab is more effective and more convenience
than zoledronic acid in delaying or preventing skeletal
morbidity in patients with bone metastases from several
types of cancers. Denosumab does not need dosing
adjustment in case of renal impairment.
Radium-223 increases overall survival in castration-re-
sistant prostate cancer and is a new bone-targeted agent for
this disease.
Multidisciplinary approach is essential. Radiation and
surgery should be considered in all patients, and indicated
when appropriate.
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